Search

Your search keyword '"Lacroix-Triki, Magali"' showing total 420 results

Search Constraints

Start Over You searched for: Author "Lacroix-Triki, Magali" Remove constraint Author: "Lacroix-Triki, Magali"
420 results on '"Lacroix-Triki, Magali"'

Search Results

1. Evaluation of the mitotic score of invasive breast carcinomas on digital slide: development and contribution of a mitosis detection algorithm

3. Fit-for-Purpose Ki-67 Immunohistochemistry Assays for Breast Cancer

4. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

5. Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial

6. Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials

8. Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer

9. Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.

10. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

11. Development of a deep‐learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2‐low cases.

12. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study

13. Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France

15. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy

16. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

17. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

18. Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein

19. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor

20. Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases

21. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

27. Supplementary Figures 1-11 from Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

31. Supplementary Table 2 from Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

35. Supplementary Tables 1-2, Figures 1-2, Material and Methods from Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

37. Data from Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

39. Supplementary Figure Legends 1-11, Table Legends 1-3, Methods from Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

42. Supplementary Table 1 from Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

44. Supplementary Table 3 from Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis

48. Abstract P2-02-07: Patients’ selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial

49. Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers

Catalog

Books, media, physical & digital resources